India's Syngene International acquires first US biologics facility for $36.5 million
India's Syngene International on Monday said it has acquired its first biologics facility in the United States from Emergent Manufacturing Operations Baltimore, a unit of Emergent BioSolutions, for $36.
Syngene Acquires First US Manufacturing Facility
The Baltimore Biologics Drug Substance facility will serve customers across human and animal health market segments.
Syngene International acquires its first biologics unit in US for $36.5 mn
The facility, equipped with multiple monoclonal antibody (mAbs) manufacturing lines, comes for a deal value of $36.5 million
Syngene Boosts Biologics Capacity with US Facility Acquisition
The facility was acquired from Emergent Manufacturing Operations Baltimore, LLC, a subsidiary of Emergent BioSolutions Inc.
Syngene International shares in focus on acquiring first US biologics facility for $36.5 million
Syngene International announced acquiring its first biologics facility in the U.S. from Emergent Manufacturing for $36.5 million. This acquisition will boost Syngene's bioreactor capacity to 50,000 liters,
India's Syngene International acquires first US biologics facility for $36.5 mln
India's Syngene International on Monday said it has acquired its first biologics facility in the United States from Emergent Manufacturing Operations Baltimore, a unit of Emergent BioSolutions , for about $50 million.
$50 million deal! THIS Indian healthcare firm acquires first US biologics facility
An Indian healthcare company has acquired its first US facility investing around US$50 million. It is a global contract research, development, and manufacturing organization (CRDMO). The company has acquired its first biologics facility in the United States from Emergent Manufacturing Operations Baltimore for $36.
Pharmaceutical Commerce21h
Syngene Purchases First US Manufacturing Facility for $36.5M
In a transaction officially set to close later this month, Syngene International Limited, a contract research, development, ...
Fierce Pharma3d
Indian contractor Syngene throws down $37M for Emergent's Baltimore biologics plant
As Emergent BioSolutions continues to pawn off manufacturing real estate in its pivot from production specialist to full-time ...
Drug manufacturer to sell Baltimore plant for $36.5M
The company has been selling off its assets after an error caused tens of millions of vaccines to get thrown out during the ...
Devdiscourse3d
Syngene Expands Global Footprint with $50M US Facility Acquisition
Syngene International has acquired its first US manufacturing facility for approximately USD 50 million. The acquisition aims ...
Medical Dialogues3d
Syngene buys its first manufacturing facility in US for USD36.5 million
Bangalore: Syngene International Limited, a global contract research, development, and manufacturing organization (CRDMO), ...
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading ...
Stocks in news: City Union Bank, Navin Fluorine, Syngene, IIFL Finance, NLC India, Sharda Cropchem and Arvind Fashions
When markets resume trading today, City Union Bank, Navin Fluorine, Syngene International, IIFL Finance, NLC India, Sharda ...